# Tempus xE

Source: https://onco.cc/drugs/tempus-xe/  
OnCo record `tempus-xe` (Test). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tempus' tumour test that reads the protein-coding part of every gene, with possible inherited findings reported from a limited list.

## Summary

Tempus xE is a whole-exome panel of more than 19,000 genes sequenced from DNA, reporting potentially actionable and biologically relevant alterations and tumour mutational burden. Sequencing of a matched normal sample keeps somatic variant calls accurate, and potential germline findings may be reported from a limited set of 110 genes chosen from ACMG recommendations, NCCN guidelines and published literature; Tempus states that xE is not a validated germline panel and that these findings should not be used to diagnose hereditary cancer risk. It needs a specimen with at least 40% tumour content after macrodissection, and it can be ordered alone or in combination with Tempus xR.

## Fields

- Kind: Test
- Status: established
- Last checked: 2026-11-03
- Tags: test
- Brand: Tempus xE
- Modality: Whole-exome tumour sequencing test (tumour and matched normal)
- Mechanism: DNA sequencing of the whole exome, more than 19,000 genes, from tumour tissue with a matched normal sample used to tell tumour-only changes from inherited ones.

## Notes

- What a result means: a tumour alteration linked to a drug or a trial is listed; a possible inherited finding needs confirmation with a dedicated germline test and genetic counselling.
- Not confirmed: the regulatory status of xE. Tempus' page does not state it.

## Sources

- Tempus: xE (archived copy, 11 April 2026): http://web.archive.org/web/20260411051124/https://www.tempus.com/oncology/genomic-profiling/xe/
- Tempus: xE: https://www.tempus.com/oncology/genomic-profiling/xe/

## Connected records

- drugs: [Tempus xT CDx](https://onco.cc/drugs/tempus-xt-cdx/)
- biomarkers: [TMB-high (tumour mutational burden >= 10 mutations per megabase)](https://onco.cc/biomarkers/tmb-high/)
- technologies: [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- companies: [Tempus AI](https://onco.cc/companies/tempus/)
- terms: [Next-generation sequencing (NGS)](https://onco.cc/terms/ngs/), [Tumour mutational burden (TMB)](https://onco.cc/terms/tmb/)

---
JSON: https://onco.cc/api/v1/entities/tempus-xe.json